Profilo
Sebastien Giguere is the founder of Valence Discovery, Inc. He received an undergraduate degree from Université Laval in 2014.
Precedenti posizioni note di Sebastien Giguere
Società | Posizione | Fine |
---|---|---|
Valence Discovery, Inc.
Valence Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Recursion Pharmaceuticals, Inc., Valence Discovery, Inc. is a Canadian company committed to unlocking the true potential of deep learning in drug design. The company is based in Montréal, Canada, and is pioneering the application of few-shot learning in drug design. Valence's AI-enabled drug design platform has been extensively validated and is currently being used to identify and design drug candidates in collaboration with industry-leading partners. The company is developing and deploying novel machine learning methods for molecular property prediction, generative chemistry, and multiparameter optimization. The company was founded by Sebastian Giguere, Prudencio Tossou, Daniel Cohen, Therence Bois, Sebastien Giguere, and Daniel Cohen has been the CEO since incorporation. Valence Discovery was acquired by Recursion Pharmaceuticals, Inc. on May 16, 2023 for $35.35 million. | Amministratore Delegato | - |
Formazione di Sebastien Giguere
Université Laval | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
Valence Discovery, Inc.
Valence Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Recursion Pharmaceuticals, Inc., Valence Discovery, Inc. is a Canadian company committed to unlocking the true potential of deep learning in drug design. The company is based in Montréal, Canada, and is pioneering the application of few-shot learning in drug design. Valence's AI-enabled drug design platform has been extensively validated and is currently being used to identify and design drug candidates in collaboration with industry-leading partners. The company is developing and deploying novel machine learning methods for molecular property prediction, generative chemistry, and multiparameter optimization. The company was founded by Sebastian Giguere, Prudencio Tossou, Daniel Cohen, Therence Bois, Sebastien Giguere, and Daniel Cohen has been the CEO since incorporation. Valence Discovery was acquired by Recursion Pharmaceuticals, Inc. on May 16, 2023 for $35.35 million. | Commercial Services |
- Borsa valori
- Insiders
- Sebastien Giguere